Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its price objective lowered by Canaccord Genuity Group from $57.00 to ...

Canaccord Genuity Group (TSE:CF – Get Free Report) had its price target increased by investment analysts at Ventum Financial from C$10.25 to C$12.00 in a report issued on Monday,BayStreet.CA reports.

Raymond James raised the firm’s price target on Canaccord Genuity (CCORF) to C$13 from C$11 and keeps a Strong Buy rating on the shares.

Firm-wide Revenue: $128 million for the quarter, up 27% year-over-year. Fiscal Year-to-Date Revenue: $857 million, up 26% ...

Canaccord Genuity Group Inc. reported net income of $16.9 million for its most recent quarter as its wealth management and ...

Canaccord Genuity Group Inc. recorded strong growth in wealth-management and capital-markets divisions for its fiscal second ...

Good morning, ladies and gentlemen. Thank you for standing by. I'd like to welcome everyone to the Canaccord Genuity Group Inc. Fiscal 2025 Second Quarter Results Conference Call. All lines have been ...

Canaccord Genuity Group Inc is set to release its Q2 2025 earnings on Nov 8, 2024.The consensus estimate for Q2 2025 revenue is $0.43 million, and the earnings are expected to come in at $0.22 per ...

In a report released on November 6, Allan Franklin from Canaccord Genuity maintained a Buy rating on Ardent Leisure Group Ltd (CEH – ...